Craig Gracey, serving as the Chief Accounting Officer for Omada Health, Inc. (OMDA), has completed a transaction to sell shares of the company's common stock. The total value of the sale reached $37,494, as documented in a recent Form 4 filing submitted to the Securities and Exchange Commission. This executive divestment occurred on June 22, 2026, marking a specific point of activity within the firm's corporate governance structure.
During this transaction, Mr. Gracey disposed of 2,083 shares at a price of $18.0 per share. Following the execution of this sale, his direct ownership stake in Omada Health stands at 7,108 shares of common stock. The transaction was executed pursuant to a 10b5-1 trading plan, a pre-arranged trading mechanism designed to facilitate insider transactions in compliance with securities regulations. Mr. Gracey adopted this specific trading plan on March 13, 2026, which dictates the timing and conditions of his future stock movements.
The executive sale takes place against a backdrop of robust financial performance for Omada Health. The company has posted a strong approximately 16% year-to-date return on its stock, indicating positive momentum in the market. Despite this recent appreciation, current trading levels suggest potential valuation concerns, with some analysis indicating the stock may be overvalued relative to its fundamentals. Omada Health is currently valued at $1.09 billion, reflecting significant market confidence in its digital health platform.
Financial results for the first quarter of 2026 further highlight the company's growth trajectory. Omada Health reported a positive earnings surprise, with earnings per share (EPS) coming in at -$0.05, surpassing the forecasted -$0.08. This performance underscores the company's ability to manage costs while driving top-line growth. Revenue reached $78 million, marking a significant 42% year-over-year increase. This impressive revenue growth of approximately 49% over the last twelve months as of Q1 2026 demonstrates the expanding demand for its services.
Market analysts have responded positively to these developments. Citizens raised its price target for Omada Health to $21 from $18, maintaining a Market Outperform rating. Analyst Constantine Davides highlighted that the company recently traded at 2.5 times the firm's 2026 revenue estimate, providing a metric for investor consideration. These insights are available through comprehensive research reports, offering deeper valuation analysis for those tracking the digital health sector.
In corporate governance developments, Omada Health held its 2026 Annual Meeting of Stockholders. During this meeting, Sean Duffy and Trevor Fetter were elected as Class I Directors. Both directors will serve until the 2029 annual meeting, ensuring continuity in the company's leadership structure. These governance updates reflect the company's ongoing progress and sustained investor interest in its long-term strategic direction.